Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer.

ABSTRACT:

Purpose

TP53 signature has a robust predictive performance for prognosis in early-stage breast cancer, but the experiment that reported this relied on public microarray data and fresh-frozen samples. Before TP53 signature can be used in a clinical setting, a simple and low-cost diagnostic system using formalin-fixed paraffin-embedded (FFPE) samples is needed. New treatments based on the biological characteristics of TP53 signature are expected to follow.

Experimental design

TP53 signature was evaluated in 174 FFPE early breast cancer specimens using digital quantification via the nCounter technique (NanoString). Patients were classified as TP53 signature mutant type (n = 64) or wild type (n = 110). Predictive power of TP53<

SUBMITTER: Yamaguchi S 

PROVIDER: S-EPMC5865663 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature